MarketsandMarkets

Biomarker and Companion Diagnostics Conference - EU Edition

5th - 6th October 2023

The Westin Grand Frankfurt, Germany

Discovering the latest technologies and biomarkers that drive translational research and precision medicine.

MarketsandMarkets brings to you the Biomarker and Companion Diagnostics Conference scheduled to be held on 5th-6th October 2023 at The Westin Grand Frankfurt, Germany. This event is designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

This conference unites advances in biomarker use for drug discovery and development, alongside biomarkers for cancer. The Expert Panel will take you through their presentations which will include problems, solutions and services in the Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases. Attendees would evidence the examples and the case studies which will help in creating the revenue. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers.
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology, and Inflammatory Diseases

  • Hear from and meet with the key industry and academic innovators in biomarkers, translational medicine, clinical development, and diagnostics.
  • Discover the latest integration of biomarkers in early drug development through case studies by major pharma on multiple therapeutic areas, including immuno-oncology, neuroscience, cardiology, immunology respiratory rare diseases, and cell and gene therapies.
  • Gain novel insights into key biomarkers for detection, monitoring, and diagnosis, including innovative applications of digital markers.
  • Benefit from case studies on topical technology innovation within digital pathology, AI & imaging, flow cytometry, multiplexing, mass spectrometry and spatial biology tools.
  • Unparalleled networking opportunities. The two-day congress offers an interactive platform for high-level scientific and business discussions. Participate in formal or informal discussions during our networking breaks and pre-organised 1-2-1 meetings.

Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

CLINICAL BIOMARKER DRUG DEVELOPMENT AND PRECISION MEDICINE

Aligning Innovation with Precision Medicine

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

09:00 - 09:30

Gene expression signatures: key success factors

Eike Staub

Eike Staub, Head, Oncology Bioinformatics, Merck Healthcare, Germany

09:30 - 10:00

Transforming Oncology with Predicine’s Liquid Biopsy Solutions

Shidong Jia

Shidong Jia, Founder, CEO, Predicine

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation

11:15 - 11:45

Analysis of biomarkers in circulating fluids-emerging trend in liquid biopsy

11:45 - 12:15

Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs

Allan Stensballe

Allan Stensballe, Associate Professor, Aalborg University

12:15 - 12:45

Lunch and Poster Presentation | One-to-One Networking Meeting

12:45 - 13:45

Why do 95% of oncology drugs fail in clinical development, and how can biomarkers help?

Philip Beer

Philip Beer, Chief Scientific Officer, Step Pharma

13:45 - 14:15

Use of omics technologies in biomarker discovery and profiling

14:15 - 14:45

Precision medicine in rare diseases – learnings and opportunities

Thomas Hach

Thomas Hach, Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis

14:45 - 15:15

Evening Refreshments and Poster Presentation | One-to-One Networking Meetings

15:15 - 15:45

Digital Biomarkers, Predictive Biomarkers, Precision Medicine, and Big Data

Katarzyna Wac

Katarzyna Wac, Full Professor, Computer Science, University of Geneva

15:45 - 16:15

When over 99% of published Biomarkers end up in the bin what can we do to reduce this waste and pick out the ones that could be rescued?

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

16:15 - 16:45

Panel Discussion: Clinical biomarker development is critical to bring precision medicine from a scientific concept into clinical practice-Views?

Louis Boon

Louis Boon, CSO , JJP Biologics

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Vaios Karanikas

Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

16:45 - 17:15

Closing Remarks from the Chairperson

17:15 - 17:15

Drinks Reception & Networking

17:15 - 17:15

End of Day 1

17:15 - 17:15

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

CDX DEVELOPMENT, INTEGRATION AND COMMERCIALIZATION: CLINICAL APPLICATIONS OF CDX

Keynote Presentation

Jürgen Scheuenpflug

Jürgen Scheuenpflug, Global Head Clinical Biomarkers & Companion Diagnostics, Merck Healthcare KGaA

09:00 - 09:30

Point-of-Care quantitative lateral flow diagnostic tests

Aart van Amerongen

Aart van Amerongen, Senior scientist BioSensing & Diagnostics (BSD) , Wageningen UR

09:30 - 10:00

Next generation technologies in metabolic disease diagnosis and therapeutic effectiveness

Aparna Duggirala

Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:30

Solution Provider Presentation

11:30 - 12:00

Regulatory considerations, approvals, reimbursement surrounding CDx

12:00 - 12:30

Challenges of measuring novel biomarkers using plate-based methods in large clinical studies

Daniel Chapman

Daniel Chapman, Post Doctoral Research Fellow, University of Oxford

12:30 - 13:00

Lunch and Poster Presentation | One-to-One Networking Meetings

13:00 - 14:00

Panel Discussion: Challenges and opportunities to integrate biomarker in clinical trial development-How to use the power of biomarker to accelerate clinical development?

14:00 - 14:30

Future directions in CDx-liquid biopsy, multi-marker panels and integration of CDx with precision medicine

14:30 - 15:00

Closing Remarks from the Chairperson

15:00 - 15:05

End of the conference

15:05 - 15:05

SPEAKERS

Fatima Sanfourche

Fatima Sanfourche

Sr. Director of QA & RA Compliance for Medical devices, Combination products, and eHealth, Bayer

Vaios Karanikas

Vaios Karanikas

Biomarker Experimental Medicine Leader, Oncology, Roche

Louis Boon

Louis Boon

CSO , JJP Biologics

Aart van Amerongen

Aart van Amerongen

Senior scientist BioSensing & Diagnostics (BSD) , Wageningen UR

Allan Stensballe

Allan Stensballe

Associate Professor, Aalborg University

Shidong Jia

Shidong Jia

Founder, CEO, Predicine

Christopher Peters

Christopher Peters

Clinical Senior Lecturer, Imperial College London

David Brassat

David Brassat

Global Biomarker Lead, Novartis

Smiths Lueong

Smiths Lueong

Research Scientist, UK-essen

Eike Staub

Eike Staub

Head, Oncology Bioinformatics, Merck Healthcare, Germany

Daniel Chapman

Daniel Chapman

Post Doctoral Research Fellow, University of Oxford

Liying Yan

Liying Yan

President, EpigenDx

Aparna Duggirala

Aparna Duggirala

Lecturer, Clinical Genetics, University of Derby

Katarzyna Wac

Katarzyna Wac

Full Professor, Computer Science, University of Geneva

Jürgen Scheuenpflug

Jürgen Scheuenpflug

Global Head Clinical Biomarkers & Companion Diagnostics, Merck Healthcare KGaA

Philip Beer

Philip Beer

Chief Scientific Officer, Step Pharma

Thomas Hach

Thomas Hach

Executive Director Patient Engagement, Cardiovascular, Renal & Metabolism Patient Engagement, Novartis

Elizabeth Sheppard

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

ENQUIRE NOW

SPONSORS

Predicine
Proteome Sciences
EpigenDx
Sengenics
Biognosys
Somalogic

PARTNERS

LOCATION

Venue

The Westin Grand Frankfurt, Germany

PAST EVENT GALLERY